Mirabegron Teva

Mirabegron, the active ingredient in Mirabegron Teva, is a β3‑adrenergic receptor agonist presented as an oral tablet for oral use. It is prescribed to manage symptoms of overactive bladder, including urinary urgency, frequency, and urge incontinence, in adult patients. The medication works by relaxing the detrusor muscle during the bladder filling phase, thereby increasing functional bladder capacity and reducing involuntary contractions.

GNH USA supplies Mirabegron Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures reliable access to quality medicines across multiple regions.

Mirabegron is used to treat conditions within the overactive bladder disease family by improving bladder storage function. - Overactive bladder: reduces urgency episodes and increases bladder capacity. - Urinary urgency: lessens the sudden need to void. - Urinary frequency: decreases the number of daytime voids. - Urge urinary incontinence: lowers the occurrence of involuntary leakage.

Common and serious adverse reactions have been reported with mirabegron therapy.

Common Side Effects: - Hypertension: increase in blood pressure. - Headache: mild to moderate intensity. - Nasopharyngitis: upper respiratory tract infection symptoms. - Constipation: reduced bowel movements. - Dry mouth: decreased salivation. - Urinary retention: difficulty emptying bladder.

Serious or Rare Side Effects: - Severe hypertension: markedly elevated blood pressure requiring medical intervention. - Acute urinary retention: sudden inability to void, may need catheterization. - Angioedema: swelling of face, lips, tongue or throat. - Myocardial infarction: rare occurrence of heart attack. - Bladder pain: persistent discomfort in the bladder region.

Before initiating mirabegron, clinicians should evaluate several safety considerations. - Monitor blood pressure: check baseline and periodic measurements. - Assess renal function: adjust use in severe impairment. - Review cardiovascular history: caution in patients with uncontrolled hypertension. - Evaluate for urinary retention risk: avoid in those with significant obstruction. - Avoid use in uncontrolled hypertension: contraindicated when systolic >180 mmHg. - Store at room temperature: keep in original packaging, protect from moisture.

Mirabegron may interact with other medicines through metabolic pathways and pharmacodynamic effects.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirabegron exposure. - Antihypertensive agents: mirabegron can reduce their efficacy, risking uncontrolled blood pressure. - Anticholinergic drugs: combined use may exacerbate urinary retention.

Moderate Interactions (Monitor Closely): - Moderate CYP2D6 inhibitors (e.g., duloxetine): may modestly raise mirabegron levels. - Diuretics: additive effect on blood pressure and electrolyte balance. - Other β3‑adrenergic agonists: potential for additive pharmacologic activity.